Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients

Xu, Jiadai; Fu, Xiaodi; Pan, Mengqiu; Zhou, Xiao; Chen, Zhaoyu; Wang, Dongmei; Zhang, Xiaomei; Chen, Qiong; Li, Yanhui; Huang, Xiaoxian; Liu, Guanghui; Lu, Jianjun; Liu, Yan; Hu, Yafang; Pan, Suyue; Wang, Qing; Wang, Qun; Xu, Yunqi

doi:10.14336/ad.2018.0615

Cited by 30 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parkinson's disease is characterized by the excessive aggregation of α-synuclein (Dehay et al, 2015). A range of mechanisms are involved in the pathogenesis of synucleinopathies, including oxidative stress, neuroinflammation and mitochondrial dysfunction (Blandini, 2013;Xu et al, 2019;Yang et al, 2020). Among them, inflammation has been recognized as the key factor (Wang et al, 2020;Zheng et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

Song

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

Background: Excessive aggregation of α-synuclein is the key pathophysiological feature of Parkinson's disease (PD). Rapid eye movement sleep behavior disorder (RBD) is also associated with synucleinopathies and considered as a powerful predictor of PD. Growing evidence suggests the diminished clearance of α-synuclein may be partly attributable to poor interstitial fluid drainage, which can be reflected by magnetic resonance imaging (MRI)-visible enlarged perivascular space (EPVS). However, the effect of MRI-visible EPVS on iRBD and PD, and their correlation with clinical characteristics remain unclear. Objective: To evaluate the clinical and neuroimaging significance of MRI-visible EPVS in iRBD and PD patients. Methods: We enrolled 33 iRBD patients, 82 PD (with and without RBD) patients, and 35 healthy controls (HCs), who underwent clinical evaluation and 3.0 Tesla MRI. Two neurologists assessed MRI-visible EPVS in centrum semiovale (CSO), basal ganglia (BG), substantia nigra (SN), and brainstem (BS). Independent risk factors for iRBD and PD were investigated using multivariable logistic regression analysis. Spearman analysis was used to test the correlation of MRI-visible EPVS with clinical characteristics of patients. Results: iRBD patients had significantly higher EPVS burdens (CSO, BG, SN, and BS) than PD patients. Higher CSO-EPVS and BS-EPVS burdens were independent risk factors for iRBD. Furthermore, higher CSO-EPVS and SN-EPVS burdens were positively correlated with the severity of clinical symptom in iRBD patients, and higher BG-EPVS burden was positively correlated with the severity of cognitive impairment in PD patients. Conclusion: iRBD and PD patients have different MRI-visible EPVS burdens, which may be related with a compensatory mechanism in glymphatic system. Lower MRI-visible EPVS burden in PD patients may be a manifestation of severe brain waste drainage dysfunction. These findings shed light on the pathophysiologic relationship between iRBD and PD with respect to neuroimaging marker of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

Song

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…Another new biomarker related to PD progression could be the decreased serum levels of mitochondrial creatine kinase. However, no significant relationship was found between this levels and the Hoehn and Yahr (HY) stage or non-motor symptoms scales (6).…”

Section: Introductionmentioning

confidence: 94%

Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment

et al. 2020

View full text Add to dashboard Cite

Background: Cognitive impairment is one of the most frequent and disabling non-motor symptoms in Parkinson disease (PD) and encompasses a continuum from mild cognitive impairment (PD-MCI) to dementia (PDD). The risk factors associated with them are not completely elucidated. Objective: To characterize the presence and clinical presentation of PD-MCI and PDD in patients with idiopathic PD, examining motor and non-motor features and determining factors associated with cognitive impairment. Methods: Multicenter, cross-sectional study in 298 PD patients who underwent clinical [Hoehn and Yahr (HY) staging and Clinical Impression of Severity Index for Parkinson Disease], neurological [Scales for Outcomes in Parkinson's Disease (SCOPA)-Motor], neuropsychological (Mini Mental State Examination, SCOPA-Cognition, Frontal Assessment Battery and Clinical Dementia Rating Scale), neuropsychiatric [SCOPA-Psychiatric complications, SCOPA-Psychosocial (SCOPA-PS), and Hospital Anxiety and Depression Scale (HADS)], and health-related quality of life [Parkinson Disease Questionnaire for quality of life (PDQ-8)] assessment. Movement Disorders Society criteria were applied to classify patients as normal cognition (NC), PD-MCI, and PDD. The association between variables was explored using multivariate binary and multinomial logistic regression models. Results: Seventy-two patients (24.2%) were classified as NC, 82 (27.5%) as PD-MCI, and 144 (48.3%) as PDD. These last two groups reported more psychosocial problems related with the disease (mean SCOPA-PS, 16.27 and 10.39, respectively), compared with NC (7.28) and lower quality-of-life outcomes (PDQ-8 48.98 and 28.42, respectively) compared to NC (19.05). The logistic regression analysis showed that both cognitive impaired groups had a more severe stage of PD measured by HY [odds ratio (OR) for MCI

show abstract

“…There are numerous wearable inertial sensors for measuring the motor features of PD ( Heldman et al, 2014 ; Klingelhoefer et al, 2016 ; Chung et al, 2018 ; Farzanehfar et al, 2018 ; Phan et al, 2018 ; Joshi et al, 2019 ; Ricci et al, 2020 ). There is a profoundly important need for biomarkers that reflect the pathogenetic process of PD in order to improve the ability to diagnose and predict ( Xu et al, 2019 ). The digital biomarkers measured by wearable sensors in prodromal PD will be a valuable tool for screening PD in the future ( Xie et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

More Sensitive Identification for Bradykinesia Compared to Tremors in Parkinson’s Disease Based on Parkinson’s KinetiGraph (PKG)

Chen

Cai

Weng

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

The effective management and therapies for Parkinson’s disease (PD) require appropriate clinical evaluation. The Parkinson’s KinetiGraph (PKG) is a wearable sensor system that can monitor the motion characteristics of PD objectively and continuously. This study was aimed to assess the correlations between PKG data and clinical scores of bradykinesia, rigidity, tremor, and fluctuation. It also aims to explore the application value of identifying early motor symptoms. An observational study of 100 PD patients wearing the PKG for ≥ 6 days was performed. It provides a series of data, such as the bradykinesia score (BKS), percent time tremor (PTT), dyskinesia score (DKS), and fluctuation and dyskinesia score (FDS). PKG data and UPDRS scores were analyzed, including UPDRS III total scores, UPDRS III-bradykinesia scores (UPDRS III-B: items 23–26, 31), UPDRS III-rigidity scores (UPDRS III-R: item 22), and scores from the Wearing-off Questionnaire (WOQ-9). This study shows that there was significant correlation between BKS and UPDRS III scores, including UPDRS III total scores, UPDRS III-B, and UPDRS III-R scores ( r = 0.479–0.588, p ≤ 0.001), especially in the early-stage group ( r = 0.682, p < 0.001). Furthermore, we found that BKS in patients with left-sided onset (33.57 ± 5.14, n = 37) is more serious than in patients with right-sided onset (29.87 ± 6.86, n = 26). Our findings support the feasibility of using the PKG to detect abnormal movements, especially bradykinesia in PD. It is suitable for the early detection, remote monitoring, and timely treatment of PD symptoms.

show abstract

Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients

Cited by 30 publications

References 39 publications

Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment

More Sensitive Identification for Bradykinesia Compared to Tremors in Parkinson’s Disease Based on Parkinson’s KinetiGraph (PKG)

Contact Info

Product

Resources

About